breast-cancer
(5)Katherine Bowdish
Katherine (Kathy) Bowdish is a molecular geneticist and biopharmaceutical leader who serves as President and CEO of PIC Therapeutics, a Natick, Massachusetts biotech developing cancer drugs that work by modulating RNA translation - targeting the eIF4E 'master switch' that tumors use to overproduce oncogene proteins. Over more than two decades she has founded and led a string of early-stage life science companies including Prolifaron (acquired by Alexion), Anaphore and Permeon Biologics, and she built and ran Sanofi Sunrise, the pharma giant's early-stage venture and partnering arm. She holds a PhD in molecular genetics from Columbia and led PIC through a $35 million Series A to push its lead program toward the clinic in drug-resistant breast cancer.
Adam Yala
Adam Yala is a UC Berkeley and UCSF assistant professor of Computational Precision Health turned founder, now CEO of Voio, a Berkeley AI startup building frontier radiology models. At MIT he created Mirai and Sybil, open-source AI tools that flag breast and lung cancer risk years early and are now studied at more than 90 hospitals across 30 countries. In late 2025 Voio emerged from stealth with $8.6M in seed funding and Pillar-0, billed as the most accurate open AI model for radiology, with a mission to make being a radiologist more empowering rather than to replace the profession.
Connie Lehman
Connie Lehman is a radiologist who spent three decades reading mammograms and decided the picture could tell a different story. As founder and CEO of Boston-based Clairity, she built the first FDA-authorized AI platform that reads a routine screening mammogram and estimates a woman's five-year risk of developing breast cancer, spotting tissue patterns invisible to the human eye. A Professor of Radiology at Harvard Medical School with more than 300 peer-reviewed publications, she left a celebrated academic career to commercialize the idea that imaging should predict cancer, not just find it. TIME named her to its 2026 TIME100 Health list and Forbes to its 50 Over 50: Innovation list.
Julián Ríos Cantú
Julián Ríos Cantú is the co-founder and CEO of Eden, the leading cloud-native radiology operating system in Latin America. Motivated by his mother's battle with breast cancer, he began building health technology at age 16, went on to become the youngest-ever winner of the Global Student Entrepreneur Awards at 18, earned a Thiel Fellowship, and went through Y Combinator in 2018. Today, Eden processes over 13 million diagnostic studies annually across 18 countries for more than 2,200 medical institutions, backed by Sierra Ventures, Khosla Ventures, Kaszek, and notable angel investors including Leonardo DiCaprio, Ashton Kutcher, and Tony Robbins.
Sean P. Bohen
Sean P. Bohen is President and CEO of Olema Oncology, a San Francisco clinical-stage biopharmaceutical company developing targeted therapies for women's cancers. An MD/PhD oncologist who spent 13 years at Genentech and four as AstraZeneca's Chief Medical Officer, he is now steering Olema's lead drug palazestrant - an oral complete estrogen receptor antagonist - through Phase 3 trials in ER+/HER2- metastatic breast cancer.